Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.

① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.

cls.cnDec 22 11:45

Express News | US FDA: Revoked Emergency Use Authorization for Lilly's Bebtelovimab as of Dec 13 - Website

Breakings36minutes ago

Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250

Futu NewsDec 21 18:33 · Ratings

ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication

Seeking AlphaDec 23 23:07

Sector Update: Health Care Stocks Fall Premarket Monday

MT NewswiresDec 23 22:21

Does Eli Lilly (NYSE:LLY) Deserve A Spot On Your Watchlist?

Simply Wall StDec 23 21:58